+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Sepsis Pipeline Insight 2021

  • ID: 4989048
  • Drug Pipelines
  • January 2021
  • Region: Global
  • 138 pages
  • DelveInsight

FEATURED COMPANIES

  • Abionyx
  • Asahi Kasei Pharma
  • Cidara Therapeutics
  • Enlivex Therapeutics
  • Inotrem
  • Revimmune
This “Sepsis - Pipeline Insight, 2021,” report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in Sepsis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
  • Global coverage
Sepsis Understanding

Sepsis: Overview

Sepsis is a life-threatning organ dysfunction caused by dysregulated host response to infection. Sepsis is sometimes called septicaemia or blood poisoning. If not recognized early, it can lead to septic shock, multiple organ failure and death. It is most frequently a serious complication of infection, particularly in low- and middle-income countries where it represents a major cause of maternal and neonatal morbidity and mortality. Implementing preventive measures against infections, such as good hygiene practices, ensuring access to vaccination programs, improved sanitation and water quality and availability, and other infection prevention and control best practices both in the community and health care settings, are key steps in reducing the occurrence of sepsis.

Symptoms
There are three stages of sepsis which are sepsis, severe sepsis, and septic shock. Symptoms of sepsis includes:
  • Fever above 101ºF (38ºC) or a temperature below 96.8ºF (36ºC)
  • Heart rate higher than 90 beats per minute
  • Breathing rate higher than 20 breaths per minute
  • Probable or confirmed infection
Severe sepsis occurs if the original sepsis remains untreated or remains unresponsive to treatments. Severe sepsis will occur when the sepsis is affecting the function of an organ.

Diagnosis
Diagnosis of sepsis demands a high level of suspicion, through the study of history and physical examination, appropriate laboratory checkups, and close follow-up of hemodynamic status of the patient.

Treatment
Sepsis is a medical emergency. It needs to be treated as such. Sepsis should be treated as quickly and efficiently as possible as soon as it has been identified. Treatment includes rapid administration of antibiotics and fluids. The risk of death from sepsis increases by an average of up to 7.6% with every hour that passes before treatment begins.

"Sepsis - Pipeline Insight, 2021" report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Sepsis pipeline landscape is provided which includes the disease overview and Sepsis treatment guidelines. The assessment part of the report embraces, in depth Sepsis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Sepsis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights
  • The companies and academics are working to assess challenges and seek opportunities that could influence Sepsis R&D. The therapies under development are focused on novel approaches to treat/improve Sepsis.
Sepsis Emerging Drugs Chapters

This segment of the Sepsis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Sepsis Emerging Drugs

Rezafungin: Cidara Therapeutics

Rezafungin is a novel, once-weekly antifungal being developed for the treatment and prevention of serious fungal infections. Rezafungin (formerly CD101) is an echinocandin drug, currently in Phase III clinical development for candidemia, invasive candidiasis and for prophylaxis of invasive fungal infections due to Candida, Aspergillus, and Pneumocystis. The U.S. Food and Drug Administration (FDA) has granted Qualified Infectious Disease Product (QIDP) and fast track designations for rezafungin.

VBI-S: Vivacelle Bio

VBI-S is made of small particles of specific lipid called micelles and liposomes for the treatment of hypotension. VBI-S is an intravenously injectable fluid comprised of phospholipid nanoparticles that were specifically designed to shift the biophysical properties of the body's fluid volume in hypovolemic shock, due to sepsis, from non-survival to survival. The therapy is currently under phase II clinical evaluation for the treatment of hypovolemia due to sepsis/septic shock.

Sepsis: Therapeutic Assessment

This segment of the report provides insights about the different Sepsis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Sepsis

There are approx. 40+ key companies which are developing the therapies for Sepsis. The companies which have their Sepsis drug candidates in the most advanced stage, i.e. Phase III include, Cidara Therapeutics.

Phases

This report covers around 40+ products under different phases of clinical development like
  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration
Sepsis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as:
  • Oral
  • Parenteral
  • Intravitreal
  • Subretinal
  • Topical.
  • Molecule Type
Products have been categorized under various Molecule types such as:
  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Sepsis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Sepsis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Sepsis drugs.

Sepsis Report Insights
  • Sepsis Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs
Sepsis Report Assessment
  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs
Key Questions

Current Treatment Scenario and Emerging Therapies:
  • How many companies are developing Sepsis drugs?
  • How many Sepsis drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Sepsis?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Sepsis therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Sepsis and their status?
  • What are the key designations that have been granted to the emerging drugs?
Key Players
  • Cidara Therapeutics
  • Vivacelle Bio
  • SciClone Pharmaceuticals
  • Asahi Kasei Pharma
  • Sanofi
  • Shionogi
  • Revimmune
  • Inotrem
  • Enlivex Therapeutics
  • Abionyx
Key Products
  • Rezafungin
  • VBI-S
  • Thymosin alpha 1
  • ART-123
  • Alirocumab
  • Cefiderocol
  • CYT107
  • Nangibotide
  • Allocetra-OTS
  • CER-001


This report will be delivered within 2 business days.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abionyx
  • Asahi Kasei Pharma
  • Cidara Therapeutics
  • Enlivex Therapeutics
  • Inotrem
  • Revimmune
Introduction

Executive Summary

Sepsis: Overview
  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management
Pipeline Therapeutics
  • Comparative Analysis
Therapeutic Assessment
  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type
Sepsis - Analytical Perspective

In-depth Commercial Assessment
  • Sepsis companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Sepsis Collaboration Deals
  • Company-Company Collaborations (Licensing / Partnering) Analysis
  • Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
  • Comparative Analysis
Rezafungin: Cidara Therapeutics
  • Product Description
  • Research and Development
  • Product Development Activities
Mid Stage Products (Phase II)
  • Comparative Analysis
VBI-S: Vivacelle Bio
  • Product Description
  • Research and Development
  • Product Development Activities
Early Stage Products (Phase I)
  • Comparative Analysis
HY209: Shaperon
  • Product Description
  • Research and Development
  • Product Development Activities
Early Stage Products (Preclinical)
  • Comparative Analysis
Selinexor: Karyopharm Therapeutics
  • Product Description
  • Research and Development
  • Product Development Activities
Inactive Products
  • Comparative Analysis
Sepsis Key Companies

Sepsis Key Products

Sepsis- Unmet Needs

Sepsis- Market Drivers and Barriers

Sepsis- Future Perspectives and Conclusion

Sepsis Analyst Views

Sepsis Key Companies

Appendix

List of Tables
Table 1 Total Products for Sepsis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products

List of Figures
Figure 1 Total Products for Sepsis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Note: Product cover images may vary from those shown
  • Cidara Therapeutics
  • Vivacelle Bio
  • SciClone Pharmaceuticals
  • Asahi Kasei Pharma
  • Sanofi
  • Shionogi
  • Revimmune
  • Inotrem
  • Enlivex Therapeutics
  • Abionyx
Note: Product cover images may vary from those shown
Adroll
adroll